The Ozempic Era: Disrupting Medtech and Bariatric Surgery
While it might seem unlikely, the stage for this disruption was set during an episode of The Dr. Oz Show. Semaglutide, Novo Nordisk’s GLP-1 receptor agonist, was initially developed for diabetes management and later explored for its potential to treat Alzheimer’s and dementia. However, it was on Dr. Oz’s popular talk show that the weight loss properties of the drug—marketed under the brand name Ozempic—became the focus, sparking a viral craze that would ripple across the healthcare industry. This blog is originally published here: https://www.lifesciencemarketr....esearch.com/insights
Like
Comment
Share
